Study guide
4.4 Impaired Practitioners & the Health Professionals' Services Program (HPSP)
Oregon Multistate Pharmacy Jurisprudence Examination MPJE
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview & Oregon Legal Framework
1.1 Oregon MPJE Format, Fees, Blueprint & 2027 Changes 1.2 Federal–Oregon Legal Hierarchy, Agencies & the Board of Pharmacy
2 Chapter 2: Pharmacist & Pharmacist-in-Charge Responsibilities
2.1 Pharmacist Responsibilities, Supervision & Prohibited Practices 2.2 Pharmacist-in-Charge: Qualifications, Duties, Inventories & Self-Inspection
3 Chapter 3: Pharmacy Technicians, Interns & Preceptors
3.1 Pharmacy Technicians (COPT & PT): Licensure, Permitted Tasks & Limits 3.2 Pharmacy Interns & Preceptors: Licensure, Scope & Supervision
4 Chapter 4: Licensure, Renewal, Discipline & Impaired Practitioners
4.1 Pharmacist Licensure by Examination, Score Transfer & Reciprocity 4.2 License Renewal, Continuing Pharmacy Education & Lapse Rules 4.3 Grounds for Discipline, Sanctions & Mandatory Reporting Deadlines 4.4 Impaired Practitioners & the Health Professionals' Services Program (HPSP)
5 Chapter 5: Prescriber Authority & Prescription Requirements
5.1 Prescriber Authority, DEA Registration & Out-of-State Prescriptions 5.2 Non-Controlled Prescriptions: Required Elements, Signatures, Expiration & Refills 5.3 Controlled Substance Prescriptions: Schedules II–V, EPCS, Emergency Orders & Oregon's CV Limit 5.4 Drug-Use Limitations & Special Prescriptions: REMS, Death with Dignity, EPT & Standing Orders 5.5 Legitimate Medical Purpose, Corresponding Responsibility & Red Flags
6 Chapter 6: Pharmacist Clinical Services & Prescriptive Authority
6.1 CDTM, Clinical Pharmacy Agreements, MTM & Laboratory Testing 6.2 Pharmacist Prescribing: Statewide Protocols, the Formulary & General Requirements 6.3 Pharmacist Prescribing of Hormonal Contraception (ORS 689.689) 6.4 Tobacco Cessation Protocol: Training, Screening, NRT & Non-NRT Prescribing 6.5 Vaccine Prescribing & Administration: Age Floors, Protocols, Training & ALERT IIS 6.6 Opioid Overdose Reversal & MOUD: Naloxone Prescribing, Standing Orders, Immunity & Buprenorphine
7 Chapter 7: Counseling, Language Access & Confidentiality
7.1 Patient Counseling: Triggers, Who May Offer or Accept a Refusal & Documentation 7.2 Language Access & Accessibility: Dual-Language Labels, Registry Interpreters & Prescription Readers 7.3 Patient Confidentiality: Oregon Rules, HIPAA, Part 2 & PDMP Privacy
8 Chapter 8: The Dispensing Process
8.1 Prospective Drug Utilization Review: Oregon's Eight Categories, Documentation & Who May Perform It 8.2 Oregon PDMP: Reporting Within 72 Hours, Covered Drugs, Access & Confidentiality 8.3 Prescription Transfers: Oregon's Next-Business-Day Duty & Federal Controlled Substance Limits 8.4 Dispensing Exceptions: 72-Hour Emergency Refills, Continuation of Therapy, Insulin & Declared Emergencies 8.5 Partial Fills: Schedule II (72-Hour, 30-Day CARA & 60-Day LTCF/Terminal) and Schedules III–V 8.6 Prescription Labeling: Oregon Elements, Physical Description, Expiration Dating & Med Paks 8.7 Packaging: PPPA Child-Resistant Containers, Waivers, Exemptions & Oregon's New-Container Rule 8.8 Conditions Prohibiting Dispensing, Quarantine, Returned Drugs & Charitable Reuse
9 Chapter 9: Nonprescription & Restricted Products
9.1 Nonprescription Drugs: Outlet Registration, Drug Facts Labeling & OTC Packaging 9.2 Dispensing-Restricted Nonprescription Products: Pseudoephedrine, Exempt Schedule V & Others
10 Chapter 10: Product Selection: Generic & Biologic Substitution
10.1 Product Selection: Generic Substitution (ORS 689.515) & Biologic Interchange (ORS 689.522)
11 Chapter 11: Acquisition, Records, Inventories & Loss Reporting
11.1 Ordering & Acquiring Controlled Substances: DEA Registration, Form 222, CSOS & the 5% Rule 11.2 Distribution Records, DSCSA, Recalls & Oregon Record Retention 11.3 Controlled Substance Inventories: Oregon's 367-Day, 93-Day, 31-Day & 15-Day Rules 11.4 Theft & Loss Reporting, Disposal, Reverse Distribution & Take-Back Receptacles
12 Chapter 12: Pharmacy Operations, Storage, Security & Special Practice Settings
12.1 Pharmacy Operations: Pharmacist Presence, Policies, Equipment, Signage, Hours & Closures 12.2 Drug Storage & Cold Chain: Temperatures, Monitoring Plans, Excursions & Vaccine Units 12.3 Security & Non-Pharmacist Access: Keys, Double Set-Ups, Institutional Night Access & DEA Controls 12.4 Hazardous Drugs: NIOSH 2024 List, USP 800 Controls, Assessment of Risk & Disposal 12.5 Compounding: OAR 855-183 (June 2026), USP 795/797/800, 503A vs. 503B & Beyond-Use Dates 12.6 Delivery of Drugs: Depots, Mail Delivery, Prescription Lockers, Kiosks & Mobile Pharmacies 12.7 Central Fill, Remote Processing, Telework & Remote Dispensing Site Pharmacies
13 Chapter 13: Drug Outlet Registration, Inspection & Institutional Practice
13.1 Drug Outlet Classes, Registration, Changes of Ownership/Location/Name & Non-Resident Pharmacies 13.2 Inspections, Self-Inspection Forms & Discipline of Drug Outlets 13.3 Institutional & Long-Term Care Practice: Drug Rooms, Night Access, E-Kits, ADCs & ED Prepacks
4.4 Impaired Practitioners & the Health Professionals' Services Program (HPSP)
Key Takeaways Explain This Topic AI
Oregon's HPSP monitors licensees diagnosed with substance use or mental health disorders. It does not diagnose or treat.
A self-referred Oregon pharmacist must attest they are not under Board investigation. HPSP reports a self-referral to the Board only if the licensee is noncompliant.
Oregon HPSP monitoring agreements require at least two years of continuous compliance, random testing, abstinence, practice limits and payment by the licensee.
Under an HPSP agreement, a licensee reports prohibited substance use within 24 hours and any arrest or conviction within three business days.
HPSP must report substantial noncompliance, such as a positive test or impairment at work, to the licensee's board within one business day.
Last updated: October 2026
Why this matters
The blueprint asks about "reporting to and participating in programs addressing the inability to practice with reasonable skill and safety." In Oregon that program is the Health Professionals' Services Program (HPSP) , the impaired health professional program authorized by ORS 676.185 to 676.200 . The Board of Pharmacy participates under OAR 855-011 . Questions test self-referral versus Board referral, what HPSP reports to the Board and when, and what a monitoring agreement requires.
What HPSP is, and what it is not
HPSP monitors licensees who have been diagnosed with alcohol or substance abuse or a mental health disorder that can impair practice (ORS 676.190(2)(a)).
HPSP does not diagnose or treat . Independent clinical evaluators diagnose, and treatment providers treat (ORS 676.190(5)).
It is a monitoring program built on a written monitoring agreement . It is not an amnesty program. The Board keeps its authority to discipline.
Impairment itself is a ground for discipline (ORS 689.405(1)(d), using the ORS 676.303 definition). The Board can also order a mental, physical, chemical-dependency or competency evaluation at the licensee's expense when it has objectively reasonable grounds (ORS 689.135(10)).
Two routes into HPSP
Feature Board referral Self-referral
Who starts it The Board, after weighing disciplinary history, severity, whether practice can be limited and likelihood of success (OAR 855-011-0020) The licensee, if the Board's rules allow self-referral
Condition Written consent to share information among HPSP, the Board, monitors, employers and evaluators, consistent with ORS 179.505 and 42 CFR part 2 (OAR 855-011-0030) Must attest that they are not, to their knowledge, under Board investigation . HPSP enrolls them on the date of that attestation
Evaluation Independent clinical evaluator approved by the Board (OAR 855-011-0040) HPSP must arrange an approved independent clinical evaluator and investigate whether impaired practice endangered the public
What the Board learns HPSP sends weekly lists of Board-referred enrollees and completers HPSP may not report enrollment or successful completion to the Board. Information goes to the Board only if the licensee is noncompliant
The monitoring agreement (ORS 676.193)
Every enrolled licensee signs an agreement requiring them to:
Consent to information exchange among the program, the board, the employer, evaluators and treatment providers.
Comply continuously for at least two years to complete the program.
Follow the recommended treatment plan.
Submit to random drug and alcohol testing under federal testing regulations.
Abstain from mind-altering, intoxicating or potentially addictive drugs, unless they are prescribed for a documented condition and approved by the program if the board has granted it that authority.
Report any use of a prohibited substance within 24 hours .
Report any misdemeanor or felony arrest or conviction within three business days .
Report license applications in other states and changes in employment or practice setting.
Accept limits on practice written into the agreement.
Pay for evaluations, toxicology testing and treatment.
A workplace monitor is free of conflicts of interest. The monitor watches the licensee's safe practice, submits monthly safe-practice reports and receives noncompliance reports that may require the licensee to stop practicing.
Reporting noncompliance
HPSP must report substantial noncompliance to the licensee's board within one business day of learning of it (ORS 676.190(2)(e)). Substantial noncompliance includes:
Criminal behavior.
Conduct that harms the public or a patient, including sexual impropriety.
Impairment at work.
A positive toxicology result.
Violating a practice restriction.
Civil commitment for mental illness.
Failing to participate after signing an agreement, or failing to enroll after referral.
The report includes a description of the noncompliance, the evaluator's diagnosis report, the monitoring agreement and the licensee's employment status.
Important
A self-referred pharmacist who complies quietly is never reported to the Board. A self-referred pharmacist who tests positive is reported within one business day , and the Board then decides on discipline.
Pharmacist duties around impairment
A pharmacist who has reasonable cause to believe that another licensee is practicing while impaired, or is otherwise engaging in unprofessional conduct, must report to that licensee's board within 10 working days (ORS 676.150). Referring the colleague informally to HPSP does not satisfy that duty.
Under ORS 676.192 (2025), a board may adopt a process letting a licensee who successfully completes the program petition to remove program-related information from board records.
Participating boards may charge licensees eligible to enroll a fee of $25 per year to support the program (ORS 676.190(9)). HPSP must be audited every four years by an independent clinical evaluator.
Exam scenario
An Oregon pharmacist realizes they are misusing alcohol and is not under investigation. They self-refer to HPSP, attest that they are not under investigation, and complete an evaluation by an approved independent evaluator. They sign a two-year monitoring agreement with random testing and a workplace monitor. Eighteen months later the pharmacist completes treatment without a lapse. The Board is never told. If the pharmacist had been arrested for DUII during the program, they would have had to report the arrest to HPSP within three business days. The pharmacist would also have owed the Board their own arrest or conviction report within 10 days under OAR 855-104-0010.